Public health consequences of chronic kidney disease

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 5, 2009, Pages 566-569

  Weiner, D E ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ADULT; AUSTRALIA; CARDIOVASCULAR DISEASE; CHINA; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COST; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; OBESITY; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY; UNITED STATES;

ADULT; COST OF ILLNESS; HUMANS; INCIDENCE; OBESITY; PREVALENCE; PUBLIC HEALTH; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; UNITED STATES;

EID: 70350238790     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.137     Document Type: Short Survey

References (25)

1. Levey, A.S., Andreoli, S.P., DuBose, T., Provenzano, R. & Collins, A.J. CKD: common, harmful, and treatable-World Kidney Day 2007. Am. J. Kidney Dis. 49, 175-179 (2007).
2. Coresh, J., Astor, B.C., Greene, T., Eknoyan, G. & Levey, A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 41, 1-12 (2003).
3. Coresh, J. et al. Prevalence of chronic kidney disease in the United States. JAMA 298, 2038-2047 (2007). (Pubitemid 350074801)
4. Zhang, L. et al. Prevalence and factors associated with CKD: a population study from Beijing. Am. J. Kidney Dis. 51, 373-384 (2008).
5. Chadban, S.J. et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J. Am. Soc. Nephrol. 14, S131-S138 (2003).
6. Levey, A.S., Schoolwerth, A.C., Burrows, N.R., Williams, D.E., Stith, K.R. & McClellan, W. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am. J. Kidney Dis. 53, 522-535 (2009).
7. Collins, A.J. et al. United States Renal Data System 2008 Annual Data Report [abstr.]. Am. J. Kidney Dis. 53(1, suppl.), vi-vii, S8-S374 (2009).
8. State-specifc incidence of diabetes among adults-participating states, 1995-1997 and 2005-2007. MMWR Morb. Mortal Wkly. Rep. 57, 1169-1173 (2008).
9. Powe, N.R. & Boulware, L.E. Population-based screening for CKD. Am. J. Kidney Dis. 53, S64-S70 (2009).
10. Boulware, L.E., Jaar, B.G., Tarver-Carr, M.E., Brancati, F.L. & Powe, N.R. Screening for proteinuria in US adults: a cost-efectiveness analysis. JAMA 290, 3101-3114 (2003).
11. Jafar, T.H. et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med. 139, 244-252 (2003).
12. Brenner, B.M. et al. Efects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
13. Lewis, E.J., Hunsicker, L.G., Bain, R.P. & Rohde, R.D. The efect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456-1462 (1993).
14. Jafar, T.H. et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 135, 73-87 (2001).
15. Rosen, A.B., Hamel, M.B., Weinstein, M.C., Cutler, D.M., Fendrick, A.M. & Vijan, S. Cost-efectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for benefciaries with diabetes. Ann. Intern. Med. 143, 89-99 (2005).
16. Sarnak, M.J. & Levey, A.S. Cardiovascular disease and chronic renal disease: a new paradigm. Am. J. Kidney Dis. 35, S117-S131 (2000).
17. Weiner, D.E. et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am. J. Kidney Dis. 48, 392-401 (2006).
18. Weiner, D.E. et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J. Am. Soc. Nephrol. 15, 1307-1315 (2004).
19. Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248 (2005). (Pubitemid 41058323)
20. Fellström, B.C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407 (2009).
21. Strippoli, G.F. et al. Efects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336, 645-651 (2008).
22. Avorn, J. et al. Nephrologist care and mortality in patients with chronic renal insufciency. Arch. Intern. Med. 162, 2002-2006 (2002).
23. Kinchen, K.S. et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann. Intern. Med. 137, 479-486 (2002).
24. Stack, A.G. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am. J. Kidney Dis. 41, 310-318 (2003).
25. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39(suppl. 1), S1-S266 (2002).